The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Cancer immunotherapy is a treatment that helps the immune system fight cancer. It includes various types of cancer immunotherapy, such as checkpoint inhibitors, CAR T-cell therapy, monoclonal antibodies and cancer vaccines. Checkpoint inhibitors block proteins on cancer cells, allowing the immune system to attack and kill them. CAR T-cell therapy uses T cells that have been genetically modified in a lab to target and kill cancer cells. Monoclonal antibodies attach to specific cancer cell targets, helping the immune system find and attack them. Cancer vaccines help the immune system recognize and attack cancer cells, either from weakened or killed cells or proteins found on cancer cells. Although a relatively new treatment, cancer immunotherapy is showing promise for various types of cancer.
Although cancer immunotherapy is considered a revolutionary treatment method that uses the body’s immune system to combat cancer, it has been around since the 1800s, but research has been slow due to a lack of understanding of the immune system. Immunotherapy can lead to long-lasting effects, including remissions or cures for advanced cancers. However, it can also cause side effects like fatigue, skin rash and lung inflammation. Despite these challenges, the field is rapidly evolving, with researchers developing more effective approaches like personalized cancer vaccines and oncolytic viruses. Cancer immunotherapy is a promising treatment option for various types of cancer, with ongoing research likely to lead to even more effective and personalized therapies.
The global market for cancer immunotherapy was valued at $130.0 billion in 2023 and is projected to reach $247.2 billion by the end of 2029. The North American market for cancer immunotherapy was valued at $71.8 billion in 2023 and is estimated to reach $140.1 billion in 2029, growing at a CAGR of 11.8% during the forecast period. The rising cancer cases globally, robust approval of immunotherapy drugs and rise in government funding and pharmaceutical R&D spending were reviewed to understand the market dynamics and trends for forecasting the market size.
In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.
The report aims to:
Cancer immunotherapy is a treatment that helps the immune system fight cancer. It includes various types of cancer immunotherapy, such as checkpoint inhibitors, CAR T-cell therapy, monoclonal antibodies and cancer vaccines. Checkpoint inhibitors block proteins on cancer cells, allowing the immune system to attack and kill them. CAR T-cell therapy uses T cells that have been genetically modified in a lab to target and kill cancer cells. Monoclonal antibodies attach to specific cancer cell targets, helping the immune system find and attack them. Cancer vaccines help the immune system recognize and attack cancer cells, either from weakened or killed cells or proteins found on cancer cells. Although a relatively new treatment, cancer immunotherapy is showing promise for various types of cancer.
Although cancer immunotherapy is considered a revolutionary treatment method that uses the body’s immune system to combat cancer, it has been around since the 1800s, but research has been slow due to a lack of understanding of the immune system. Immunotherapy can lead to long-lasting effects, including remissions or cures for advanced cancers. However, it can also cause side effects like fatigue, skin rash and lung inflammation. Despite these challenges, the field is rapidly evolving, with researchers developing more effective approaches like personalized cancer vaccines and oncolytic viruses. Cancer immunotherapy is a promising treatment option for various types of cancer, with ongoing research likely to lead to even more effective and personalized therapies.
The global market for cancer immunotherapy was valued at $130.0 billion in 2023 and is projected to reach $247.2 billion by the end of 2029. The North American market for cancer immunotherapy was valued at $71.8 billion in 2023 and is estimated to reach $140.1 billion in 2029, growing at a CAGR of 11.8% during the forecast period. The rising cancer cases globally, robust approval of immunotherapy drugs and rise in government funding and pharmaceutical R&D spending were reviewed to understand the market dynamics and trends for forecasting the market size.
Report Scope
This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy’s current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024-2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.
The report aims to:
- Analyze therapies and types of cancer.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts for 2029.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the cancer immunotherapy market.
The report includes:
- 75 data tables and 54 additional tables
- An analysis of the global cancer immunotherapy market
- Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
- Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Johnson & Johnson Services Inc.
- Lilly
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 203 |
| Published | April 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 144.2 Billion |
| Forecasted Market Value ( USD | $ 247.2 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
